Faculty Collaboration Database

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. Cancer 2020 Dec 01;126(23):5077-5087

Date

09/24/2020

Pubmed ID

32965680

Pubmed Central ID

PMC8063213

DOI

10.1002/cncr.33171

Scopus ID

2-s2.0-85091306660 (requires institutional sign-in at Scopus site)   52 Citations

Abstract

BACKGROUND: Upfront autologous hematopoietic stem cell transplantation (AHCT) remains an important therapy in the management of patients with multiple myeloma (MM), a disease of older adults.

METHODS: The authors investigated the outcomes of AHCT in patients with MM who were aged ≥70 years. The Center for International Blood and Marrow Transplant Research (CIBMTR) database registered 15,999 patients with MM in the United States within 12 months of diagnosis during 2013 through 2017; a total of 2092 patients were aged ≥70 years. Nonrecurrence mortality (NRM), disease recurrence and/or progression (relapse; REL), progression-free survival (PFS), and overall survival (OS) were modeled using Cox proportional hazards models with age at transplantation as the main effect. Because of the large sample size, a P value <.01 was considered to be statistically significant a priori.

RESULTS: An increase in AHCT was noted in 2017 (28%) compared with 2013 (15%) among patients aged ≥70 years. Although approximately 82% of patients received melphalan (Mel) at a dose of 200 mg/m² overall, 58% of the patients aged ≥70 years received Mel at a dose of 140 mg/m² . On multivariate analysis, patients aged ≥70 years demonstrated no difference with regard to NRM (hazard ratio [HR] 1.3; 99% confidence interval [99% CI], 1-1.7 [P = .06]), REL (HR, 1.03; 99% CI, 0.9-1.1 [P = 0.6]), PFS (HR, 1.06; 99% CI, 1-1.2 [P = 0.2]), and OS (HR, 1.2; 99% CI, 1-1.4 [P = .02]) compared with the reference group (those aged 60-69 years). In patients aged ≥70 years, Mel administered at a dose of 140 mg/m² was found to be associated with worse outcomes compared with Mel administered at a dose of 200 mg/m² , including day 100 NRM (1% [95% CI, 1%-2%] vs 0% [95% CI, 0%-1%]; P = .003]), 2-year PFS (64% [95% CI, 60%-67%] vs 69% [95% CI, 66%-73%]; P = .003), and 2-year OS (85% [95% CI, 82%-87%] vs 89% [95% CI, 86%-91%]; P = .01]), likely representing frailty.

CONCLUSIONS: The results of the current study demonstrated that AHCT remains an effective consolidation therapy among patients with MM across all age groups.

Author List

Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A

Authors

Anita D'Souza MD Professor in the Medicine department at Medical College of Wisconsin
Parameswaran Hari MD Adjunct Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Aged
Aged, 80 and over
Dose-Response Relationship, Drug
Female
Hematopoietic Stem Cell Transplantation
Humans
Male
Melphalan
Middle Aged
Multiple Myeloma
Neoplasm Recurrence, Local
Transplantation, Autologous
Treatment Outcome
United States